Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.14 USD

806.14
3,911,551

-12.79 (-1.56%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates

Veeva Systems' (VEEV) core Subscription business segment performed impressively in Q1.

3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020

Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.

Zacks.com headshot

Sanofi's Dupixent Gets FDA Approval for Eczema in Children

Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.

Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Zacks.com featured highlights include: Eli Lilly and Company, Quidel, Everbridge and Sprouts Farmers Market

Zacks.com featured highlights include: Eli Lilly and Company, Quidel, Everbridge and Sprouts Farmers Market

Top 4 Momentum Anomaly Stocks to Enhance Portfolio Returns

These fast movers are currently witnessing a short-term pullback in price. So, this could be a solid entry point for garnering better returns.

Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?

Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Why Is Lilly (LLY) Down 5.5% Since Last Earnings Report?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com headshot

Medtronic (MDT) Q4 Earnings Miss Estimates, Revenues Beat

Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.

Can Teva (TEVA) Return to Growth in This Year or Next?

Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.

Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates

McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.

J&J to Stop Sale of Talc-Based Baby Powder in North America

J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.

AstraZeneca's Enhertu Gets Breakthrough Therapy Tag for NSCLC

The FDA assigns a Breakthrough Therapy status to AstraZeneca's (AZN) Enhertu for treating patients with metastatic NSCLC whose tumors have a HER2 mutation.

Zacks.com featured highlights include: Clorox, Sprouts Farmers, Eli Lilly, Gold Fields and AngloGold

Zacks.com featured highlights include: Clorox, Sprouts Farmers, Eli Lilly, Gold Fields and AngloGold

Kinjel Shah headshot

Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY

FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.

STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise

STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.

The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY

The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY

GNC Holdings' (GNC) Q1 Earnings and Sales Miss Estimates

All the operating segments of GNC Holdings (GNC) register significant year-over-year sales decline in Q1 on coronavirus-led business disruption.

AMN Healthcare (AMN) Q1 Earnings In Line With Estimates

AMN Healthcare (AMN) gained from core operating segments in Q1.

Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss

Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.

Nilanjan Banerjee headshot

Fight Off the Coronavirus Blues With 5 Low-Beta Stocks

It is an ideal time to invest in low-beta stocks since they might provide a shield against coronavirus-induced market volatility.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines

Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.